Baas et al. demonstrated the overall concordance rate of 93% (range, 76%–100%) for the KRAS mutation status between primary colorectal tumours and corresponding metastatic sites by summarising 21 studies that reported concordance of the KRAS mutation status [26]. The gene discussed is KRAS; the disease is colorectal neoplasm.